PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno

First Page		Document Content
Date: 2018-07-18 19:08:19		PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno Add to Reading List Source URL: www.abbvie.ca Download Document from Source Website File Size: 328,56 KB Share Document on Facebook